Prevalence, T2-biomarkers and cost of severe asthma in the era of biologics: The BRAVO-1 study.
The last decade has seen a new era of classifications of asthma pathophysiology which have changed the treatment options available. To update the figures of prevalence of T2 asthma, comorbidities, biomarker characterization and costs of severe asthma in patients=12-years-old adapted to this new situ...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p1568 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/1568 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191104735&doi=10.18176%2fjiaci.0871&partnerID=40&md5=1392e9c7cd6881ba0beb7b43e66eb31d |
| Access Level: | acceso abierto |
| Palabra clave: | Asthma comorbidities, Asthma costs, Asthma prevalence, Severe asthma, Type 2 asthma, Uncontrolled asthma |
| Sumario: | The last decade has seen a new era of classifications of asthma pathophysiology which have changed the treatment options available. To update the figures of prevalence of T2 asthma, comorbidities, biomarker characterization and costs of severe asthma in patients=12-years-old adapted to this new situation. |
|---|